Blab Business
Neuronetics Reports Q1 2026 Revenue Growth Amid Profitability Push, Announces Workforce Cut and Strategic Partnerships
Neuronetics Inc. (NASDAQ: STIM) released its first‑quarter 2026 financial results on May 5, 2026, reporting a revenue increase of 8 % to $34.5 million compared with $32.0 million in the same period a year earlier. The company’s earnings per share fell short of expectations, posting a loss of $0.16 per share versus the $0.13 loss forecast by analysts.
The company’s quarterly earnings call highlighted the revenue growth as a result of expanding NeuroStar® TMS therapy deployments. NeuroStar is the only FDA‑approved transcranial magnetic stimulation (TMS) device for medication‑refractory depression, and the company has continued to add new sites and patients. While revenue rose, operating expenses also increased, contributing to the earnings miss.
On April 2, 2026, Neuronetics announced a workforce reduction that would affect up to 5 % of its employees. The company said the reduction would be completed by mid‑2026 and is part of a broader effort to optimize its cost structure. The announcement followed a 2024 workforce adjustment that had already cut 5 % of staff.
In a May 14, 2026 press release, Neuronetics disclosed a strategic collaboration with ANT Neuro. The partnership aims to integrate ANT’s neuronavigation platform with NeuroStar TMS treatment, allowing clinicians to target stimulation sites more precisely. The collaboration is expected to enhance the clinical value of NeuroStar and support the company’s growth strategy.
Neuronetics also confirmed its role as a silver sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting held on June 2, 2026. The company presented real‑world data from its largest TMS database, reinforcing NeuroStar’s leadership in evidence‑based mental‑health care. In addition to the data presentation, Neuronetics will participate in the PULSES Course, a hands‑on training program that demonstrates NeuroStar’s navigation capabilities.
On July 6, 2026, Neuronetics announced that its management team would attend the B. Riley Securities Mind, Muscle & Vision Summit, an invitation‑only institutional investor event in Boston. The company’s participation is intended to provide investors with an update on its clinical and commercial progress.
Insider trading activity was reported on May 3, 2026, when Jorey Chernett purchased $62,300 of Neuronetics common stock. The transaction was disclosed in a regulatory filing and does not indicate any material change in the company’s outlook.
Neuronetics is a vertically integrated medical‑technology company headquartered in Malvern, Pennsylvania, incorporated in Delaware. The company’s strategic focus remains on developing and commercializing neuromodulation therapies for psychiatric disorders. Its flagship product, NeuroStar, delivers non‑invasive magnetic stimulation to treat depression that has not responded to medication.
The company’s recent developments—revenue growth, workforce optimization, a new technology partnership, and active engagement in industry forums—illustrate its ongoing efforts to strengthen its market position while pursuing profitability. Investors will be watching the company’s next earnings announcement, expected in the second quarter of 2026, for further guidance on revenue trends, cost management, and the impact of the ANT Neuro collaboration.
Neuronetics’ current stock price reflects market expectations for continued revenue expansion, but the company’s earnings miss and workforce reduction signal that it is still refining its cost base. The company’s upcoming earnings call and investor events will likely provide additional insight into its financial trajectory and strategic priorities.
The company’s quarterly earnings call highlighted the revenue growth as a result of expanding NeuroStar® TMS therapy deployments. NeuroStar is the only FDA‑approved transcranial magnetic stimulation (TMS) device for medication‑refractory depression, and the company has continued to add new sites and patients. While revenue rose, operating expenses also increased, contributing to the earnings miss.
On April 2, 2026, Neuronetics announced a workforce reduction that would affect up to 5 % of its employees. The company said the reduction would be completed by mid‑2026 and is part of a broader effort to optimize its cost structure. The announcement followed a 2024 workforce adjustment that had already cut 5 % of staff.
In a May 14, 2026 press release, Neuronetics disclosed a strategic collaboration with ANT Neuro. The partnership aims to integrate ANT’s neuronavigation platform with NeuroStar TMS treatment, allowing clinicians to target stimulation sites more precisely. The collaboration is expected to enhance the clinical value of NeuroStar and support the company’s growth strategy.
Neuronetics also confirmed its role as a silver sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting held on June 2, 2026. The company presented real‑world data from its largest TMS database, reinforcing NeuroStar’s leadership in evidence‑based mental‑health care. In addition to the data presentation, Neuronetics will participate in the PULSES Course, a hands‑on training program that demonstrates NeuroStar’s navigation capabilities.
On July 6, 2026, Neuronetics announced that its management team would attend the B. Riley Securities Mind, Muscle & Vision Summit, an invitation‑only institutional investor event in Boston. The company’s participation is intended to provide investors with an update on its clinical and commercial progress.
Insider trading activity was reported on May 3, 2026, when Jorey Chernett purchased $62,300 of Neuronetics common stock. The transaction was disclosed in a regulatory filing and does not indicate any material change in the company’s outlook.
Neuronetics is a vertically integrated medical‑technology company headquartered in Malvern, Pennsylvania, incorporated in Delaware. The company’s strategic focus remains on developing and commercializing neuromodulation therapies for psychiatric disorders. Its flagship product, NeuroStar, delivers non‑invasive magnetic stimulation to treat depression that has not responded to medication.
The company’s recent developments—revenue growth, workforce optimization, a new technology partnership, and active engagement in industry forums—illustrate its ongoing efforts to strengthen its market position while pursuing profitability. Investors will be watching the company’s next earnings announcement, expected in the second quarter of 2026, for further guidance on revenue trends, cost management, and the impact of the ANT Neuro collaboration.
Neuronetics’ current stock price reflects market expectations for continued revenue expansion, but the company’s earnings miss and workforce reduction signal that it is still refining its cost base. The company’s upcoming earnings call and investor events will likely provide additional insight into its financial trajectory and strategic priorities.
